STAT+: Alzheimer’s researchers try out an unfamiliar sensation: optimism
SAN FRANCISCO — Scientific meetings about Alzheimer’s disease can be funereal affairs, with researchers from around the world gathering in hopes that the latest in a long line of negative clinical trials might light the path to a long-awaited success.
This year was different. Nearly 2,000 people showed up to the Clinical Trials in Alzheimer’s Disease meeting, a conference record, to hear about lecanemab, a drug from Eisai and Biogen that appears to have broken the decades-long cycle of disappointment.
Continue to STAT+ to read the full story…
Read Original Article: STAT+: Alzheimer’s researchers try out an unfamiliar sensation: optimism »